A Phase II, Open-label, Single Arm, Multicenter Study of Avelumab With Hypofractionated Radiation in Adult Subjects With Transformed IDH Mutant Glioblastoma
Latest Information Update: 01 Jul 2022
At a glance
- Drugs Avelumab (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- 06 May 2020 Status changed from active, no longer recruiting to completed.
- 16 May 2019 Planned End Date changed from 1 Feb 2020 to 1 Aug 2020.
- 16 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.